EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy

Hongying Sun iD, Umang Gada iD, Riham Alieldin iD, Tianming Zhao iD, Hannah Teets iD, James D Bearden iD, Benjamin T Esparaz, Jamal Misleh iD, Kah Poh Loh iD, Allison Magnuson iD, Mostafa R Mohamed iD, Nikesha Gilmore iD und 4 weitere

JNCI Cancer Spectrum · 2025

DOI: 10.1093/jncics/pkaf105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Hongying Sun und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Supportive Care in Cancer, Department of Surgery, University of Rochester Medical Center, Rochester, NY, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, Lymphoma, Cognition, Cognitive Dysfunction. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer-related cognitive impairment is a significant concern, yet data assessing long-term changes from pretreatment baselines are limited.

Methods

In this large nationwide study, patients with breast cancer and lymphoma and controls were assessed at pre-chemotherapy, post-chemotherapy, 6-month, 1-year, and 2-year follow-ups. Cognitive function was measured using self-reported and performance-based assessments. The analysis included 225 participants: breast cancer (41 patients/36 controls) and lymphoma (73 patients/75 controls). Cognitive trajectories were estimated using longitudinal linear mixed models, adjusting for demographic, clinical, and psychosocial factors. A minimal clinically important difference cutoff identified changes over time in perceived cognitive impairment.

Results

Patients with breast cancer reported greater cognitive complaints than controls, with declines in FACT-Cog Total (β = −17.17, P < .001), Perceived Cognitive Impairment (β = −11.09, P < .001), and Perceived Cognitive Abilities (β = −3.60, P = .03) from pre-chemotherapy to 2-year follow-up. Declines were observed in memory (Rey Auditory Verbal Learning Test [RAVLT] Immediate Recall: β = −1.53, P = .04) and executive function (phone fluency: β = −1.53, P = .02) at 1 year. Patients with lymphoma also showed more complaints, with declines in Perceived Cognitive Impairment (β = −6.19, P = .01), poorer RAVLT Immediate (β = −1.62, P < .001), Delayed Recall (β = −1.72, P < .001), and phone fluency (β = −2.46, P < .001) from pre-chemotherapy to 1-year follow-up.

Conclusion

Compared with controls, patients with breast cancer and lymphoma showed persistent cognitive worsening up to 1-year posttreatment, and patients with breast cancer reported perceived impairment at 2 years compared with controls.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLymphomaCognitionCognitive DysfunctionChemotherapy-Related Cognitive ImpairmentAntineoplastic AgentsHumansFemaleMiddle AgedLongitudinal StudiesAgedAdultCase-Control StudiesNeuropsychological TestsFollow-Up StudiesSelf Report

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Supportive Care in Cancer, Department of Surgery, University of Rochester Medical Center, Rochester, NY, United States.
  • Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, United States.
  • Upstate Carolina National Cancer Institute Community Oncology Research Program, Spartanburg Regional Medical Center, Spartanburg, SC, United States.
  • Heartland Cancer Research National Cancer Institute Community Oncology Research Program, Peoria, IL, United States.
  • Delaware/Christiana Care National Cancer Institute Community Oncology Research Program, Helen Graham Cancer Center, Newark, DE, United States.
  • Division of Hematology and Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY, United States.

ORCID-Profile: Hongying Sun, Umang Gada, Riham Alieldin, Tianming Zhao, Hannah Teets, James D Bearden, Jamal Misleh, Kah Poh Loh, Allison Magnuson, Mostafa R Mohamed, Nikesha Gilmore, Timothy B Winslow, Annalynn M Williams, Chin-Shang Li, Michelle C Janelsins

Förderung

  • NCI NIH HHS

Zitieren

APA

Sun, H., Gada, U., Alieldin, R., Zhao, T., Teets, H., Bearden, J. D., Esparaz, B. T., Misleh, J., Loh, K. P., Magnuson, A., Mohamed, M. R., Gilmore, N., Winslow, T. B., Williams, A. M., Li, C. S., & Janelsins, M. C. (2025). Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf105

Vancouver

Sun H, Gada U, Alieldin R, Zhao T, Teets H, Bearden JD, et al. Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkaf105

BibTeX
@article{Sun2025,
  author = {Sun, Hongying and Gada, Umang and Alieldin, Riham and Zhao, Tianming and Teets, Hannah and Bearden, James D and Esparaz, Benjamin T and Misleh, Jamal and Loh, Kah Poh and Magnuson, Allison and Mohamed, Mostafa R and Gilmore, Nikesha and Winslow, Timothy B and Williams, Annalynn M and Li, Chin-Shang and Janelsins, Michelle C},
  title = {Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy},
  journal = {JNCI Cancer Spectrum},
  year = {2025},
  doi = {10.1093/jncics/pkaf105}
}
Kostenlos starten →